Monday saw four major deals totaling over $80 billion announced in the U.S. market, pushing this year's M&A frenzy to new heights. Against this backdrop, the bidding war between pharmaceutical giants Pfizer and Novo Nordisk for "weight-loss drug upstart" Metsera Inc. has entered a white-hot phase.

According to sources familiar with the matter, Pfizer submitted a revised offer before Wednesday's deadline, matching Novo Nordisk's proposal at $86.20 per share, with a total potential value of up to $10 billion. This move keeps Pfizer in the running after Metsera's board initially deemed its Danish rival's offer superior. Both companies are fiercely competing to acquire the biotech firm with its promising pipeline.

The latest development quickly ignited market sentiment. Following news of Pfizer's revised bid, Metsera's stock surged 8% in after-hours trading, surpassing $77 per share.

**A Pivotal Battle in a $100 Billion Market** At the heart of this acquisition battle is Metsera's promising weight-loss drug pipeline, including a potential game-changing monthly injectable. In a market currently dominated by Novo Nordisk's Ozempic and Eli Lilly, any company offering more convenient and effective treatments could gain a significant competitive edge.

For Novo Nordisk, acquiring Metsera is a defensive move to solidify its market leadership. For Pfizer, it represents a critical offensive strategy to rapidly enter this golden market, projected to exceed $100 billion by the end of the decade. Securing Metsera would provide a valuable strategic advantage in future competition.

**A Twisting Bidding Process** The bidding war has been marked by dramatic turns. Initially, Pfizer reached a preliminary agreement with Metsera in September. However, last week, Novo Nordisk unexpectedly launched an unsolicited, non-binding offer, attempting to "hijack" the deal and sparking a fierce bidding contest.

Reports indicate that both sides raised their offers this Tuesday. Novo Nordisk's proposal—$62.20 per share upfront plus $24 in milestone payments, totaling $86.20 per share—was deemed the "superior offer" by Metsera's board. Pfizer's initial bid of $70 per share valued Metsera at approximately $8.1 billion. Just a day later, Pfizer swiftly matched Novo Nordisk's terms. Under the merger agreement, if Novo Nordisk raises its offer again, Pfizer will have two days to decide whether to match. A shareholder vote on the deal is scheduled for November 13.

**Legal and Regulatory Hurdles** Beyond the financial bids, legal and regulatory battles are equally intense. Pfizer has filed a lawsuit, accusing Novo Nordisk of designing an "unprecedented and illegal" two-step payment structure to evade antitrust scrutiny. Despite a setback in Wednesday's hearing, Pfizer stated it would "continue to vigorously pursue its claims through ongoing litigation and a pending parallel antitrust case in Delaware federal court."

Regulatory scrutiny has further complicated the situation. The FTC has warned Novo Nordisk and Metsera that their deal structure "may violate" competition laws. Novo Nordisk responded that it is engaged in "constructive dialogue" with the FTC and believes its proposal complies with antitrust rules. Pfizer welcomed the regulatory intervention, stating it "also shares serious concerns."

**A Microcosm of Global M&A Boom** The battle for Metsera between Pfizer and Novo Nordisk reflects the broader resurgence in global M&A activity. Data shows that worldwide M&A deals have reached $3.8 trillion year-to-date, up approximately 38% year-over-year. Companies are actively leveraging this window to reshape industries through transformative strategic acquisitions, from AI infrastructure to biotech, highlighting capital's strong pursuit of high-growth potential sectors.